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Study Objectives: To evaluate the association between objective sleep measures and metabolic syndrome (MS), hypertension, diabetes, and 
obesity.
Design: Cross-sectional study.
Setting: General population sample.
Participants: There were 2,162 patients (51.2% women, mean age 58.4 ± 11.1).
Interventions: Patients were evaluated for hypertension, diabetes, overweight/obesity, and MS, and underwent a full polysomnography (PSG).
Measurements and Results: PSG measured variables included: total sleep time (TST), percentage and time spent in slow wave sleep (SWS) 
and in rapid eye movement (REM) sleep, sleep efficiency and arousal index (ArI). In univariate analyses, MS was associated with decreased TST, 
SWS, REM sleep, and sleep efficiency, and increased ArI. After adjustment for age, sex, smoking, alcohol, physical activity, drugs that affect sleep 
and depression, the ArI remained significantly higher, but the difference disappeared in patients without significant sleep disordered breathing 
(SDB). Differences in sleep structure were also found according to the presence or absence of hypertension, diabetes, and overweight/obesity in 
univariate analysis. However, these differences were attenuated after multivariate adjustment and after excluding subjects with significant SDB.
Conclusions: In this population-based sample we found significant associations between sleep structure and metabolic syndrome (MS), 
hypertension, diabetes, and obesity. However, these associations were cancelled after multivariate adjustment. We conclude that normal 
variations in sleep contribute little if any to MS and associated disorders.
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INTRODUCTION
Cardiovascular disease (CVD) is the main cause of death 
worldwide, and is expected to increase in the forthcoming 
years.1 Lifestyle factors such as tobacco use, high-fat diet, and 
physical inactivity strongly increase risk factors for CVD, but 
they may not fully account for their development.2 It is there-
fore important to identify new underlying determinants of 
CVD.
Recent research identified relationships between sleep quan-
tity and CVD risk factors. Numerous population studies, sum-
marized in recent meta-analyses, suggested that sleep duration 
may be associated with obesity,3 hypertension,4 type 2 dia-
betes,5 the metabolic syndrome (MS),6 cardiovascular outcomes 
(including coronary heart disease, stroke, and total CVD),7 and 
overall mortality.8 In particular, for most of these outcomes 
there seems to be a U-shaped relationship with sleep duration.
Some of the aforementioned studies evaluating the associa-
tion between sleep duration and cardiovascular and metabolic 
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outcomes yielded conflicting results that can be explained by 
methodological heterogeneity. Caution has been expressed, 
from different perspectives, about the interpretation of these 
findings in critical reviews.9,10 One important limitation of 
prior epidemiological studies is that the definition of ‘‘short’’ 
and ‘‘long’’ sleep varies across studies. More importantly, al-
most all previous studies are based on subjective assessments 
of the duration of sleep, generally based on responses to a 
single question or by questionnaires that have not been vali-
dated against objective sleep measures.
Finally, it was suggested that the effect of sleep on CVD risk 
may be mediated by poor sleep quality. For example, difficul-
ties in initiating or maintaining sleep were associated with a 
greater risk of type 2 diabetes.5 Again, these conclusions are 
based on subjective assessments and do not allow the identi-
fication of sleep variables directly linked with CVD risk out-
comes. Laboratory studies in young healthy adults indicated 
that selective suppression of slow wave sleep (SWS) without 
any change in total sleep time (TST) affects glucose homeo-
stasis, potentially increasing the risk of type 2 diabetes,11 and 
can produce a significant reduction in blood pressure (BP) dip-
ping.12 Even if these findings demonstrate that sleep structure, 
independently of sleep duration, can play a role in metabolic 
disorders, they have not been replicated in large general popu-
lation studies.
Thus, the aim of this study was to explore the asso-
ciation between sleep structure, objectively measured by 
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polysomnography (PSG) and several CVD risk factors, spe-
cifically MS, hypertension, diabetes, and obesity in a large un-
selected middle-aged general population sample. We analyzed 
these associations in the entire sample and after excluding sub-
jects with a significant oxygen desaturation index (ODI > 15/h), 
as intermittent hypoxia related to respiratory disturbances (ap-
neas/hypopneas) plays an independent role in the pathophysi-
ology of CVD.13
METHODS
Population Sampling
The HypnoLaus Sleep Cohort study is based on the first 
follow-up of the epidemiologic CoLaus/PsyCoLaus study. 
Details of the CoLaus/PsyCoLaus study were previously de-
scribed.14,15 Briefly, the CoLaus/PsyCoLaus study included a 
random sample of 6,733 subjects (range age: 35–75 y) selected 
from the residents of Lausanne city (Switzerland) between 2003 
and 2006. HypnoLaus evaluated the subjective and objective 
sleep characteristics of the study population. During the first 
follow-up of the cohort, 5 y after the initial phase, all subjects 
who responded underwent a new physical (n = 5,064) and psy-
chiatric (n = 4,000) examination and were given questionnaires 
by trained interviewers, which included questions on demo-
graphic, medical, and treatment history as well as smoking and 
alcohol consumption. Sleep related complaints and habits were 
investigated using the Pittsburgh Sleep Quality Index (PSQI),16 
the Epworth Sleepiness Scale (ESS),17 and the Berlin question-
naire for sleep disordered breathing (SDB).18
CoLaus/PsyCoLaus and HypnoLaus were approved by the 
Ethics Committee of the University of Lausanne and a written 
informed consent was obtained from all participants at the 
baseline and the follow-up assessments.
Polysomnography
Three thousand fifty-one consecutive subjects were invited 
to undergo a full night in-home PSG recording. No selection of 
the subjects was made based on the questionnaires and the in-
vestigators were blinded to the questionnaires’ results. During 
a visit at the Center for Investigation and Research in Sleep 
(Lausanne University Hospital, Switzerland), trained techni-
cians equipped the subjects with the PSG recorder (Titanium, 
Embla Flaga, Reykjavik, Iceland) between 17:00 and 20:00. All 
sleep recordings took place in the subjects’ home environment 
and included a total of 18 channels: six electroencephalography, 
two electrooculography, three surface electromyography (one 
submental, two for right and left anterior tibialis muscles), one 
for electrocardiogram, nasal pressure, thoracic and abdominal 
belts, body position, oxygen saturation, and pulse rate.
All PSG recordings were visually scored by two trained 
sleep technicians (DA and NT) using Somnologica software 
(Version 5.1.1, by Embla Flaga, Reykjavik, Iceland) and re-
viewed by a trained sleep physician (JHR). Random quality 
checks were performed by a second physician (RH). Quality 
control for concordance rate between the two PSG scorers was 
implemented periodically to ensure that both scorers achieved 
at least a 90% level of agreement for sleep stages and respira-
tory events and an 85% level of agreement for arousals.19 Sleep 
stages, leg movements, and arousals were scored according 
to the 2007 American Academy of Sleep Medicine (AASM) 
criteria.20 The ODI represents the number ≥ 3% oxygen satura-
tion drops per hour of sleep. Apneas/hypopneas were scored 
according to the AASM 2013 rules.21 The average number of 
apneas/hypopneas per hour of sleep (apnea-hypopnea index 
[AHI]) was calculated.
CVD Risk Factors
BP was measured in triplicate on the left arm and values 
averaged between the last two readings. Arterial hypertension 
was defined as a systolic BP (SBP) ≥ 140 mmHg and/or a dia-
stolic BP (DBP) ≥ 90 mmHg or current use of antihypertensive 
medication. A fasting blood sample was collected for various 
analyses (including glucose, total cholesterol, high-density li-
poprotein (HDL) cholesterol, and triglycerides). Diabetes was 
defined as a fasting blood glucose level ≥ 7 mmol/L (126 mg/
dL) or current use of antidiabetic medication. The body mass 
index (BMI) was calculated and subjects were classified as 
overweight if BMI was between 25 and 30 kg/m2 and obese if 
BMI ≥ 30 kg/m2. The MS was defined according to the Adult 
Treatment Panel III report (ATP-III)22 in the presence of three 
of the following five factors: abdominal obesity (waist circum-
ference > 102 cm in men and > 88 cm in women), elevated 
triglycerides (≥ 1.7 mmol/L, > 150 mg/dL), reduced HDL cho-
lesterol (< 1.03 mmol/L (40 mg/dL) in men and < 1.20 mmol/L 
(50 mg/dL) in women), elevated BP (≥ 130/≥ 85 mmHg) (or 
hypertension), or elevated fasting glucose (≥ 5.6 mmol/L) (or 
type 2 diabetes mellitus).
Other Variables
Smoking habit was self-reported and was dichotomized as 
current smoker/ex-smoker or never smoker. Alcohol drinking 
was dichotomized as currently drinking or no alcohol con-
sumption. Regular exercise was defined as reports of exercising 
three or more times a week. Medication use, recorded at the 
time of sleep studies, was coded according to the World Health 
Organization Anatomical Therapeutic Chemical (ATC) Clas-
sification System (http://www.whocc.no/atcddd). Diagnosis of 
lifetime major depressive disorder was assigned according to 
Diagnostic and Statistical Manual of Mental Disorders, Fourth 
Edition (DSM-IV) criteria with information collected using 
the French translation23 of the semistructured Diagnostic In-
terview for Genetic Studies (DIGS).24 PSGs were recorded 
between Mondays and Fridays. Because Saturday is generally 
considered to be a day off, the day of week (Friday versus other 
weekdays) was considered as a covariate.
Statistical Analysis
All statistical tests were performed using Stata 11 (Stata-
Corp, College Station, TX, USA). For descriptive statistics, 
continuous variables were summarized as mean ± standard 
deviation, whereas categorical variables were summarized 
as number of subjects and percentages. Descriptive statistics 
were also used for sleep characteristics of the subjects based on 
presence or absence of MS, hypertension, diabetes, and obe-
sity. Student t test or one-way analysis of variance were used to 
evaluate univariate differences between PSG variables. These 
included sleep duration or TST: total minutes of any stage of 
sleep from sleep onset to morning awakening; percentage of 
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stage N3/SWS: percentage of TST spent in stage N3/SWS; 
SWS, min: time in min spent in stage N3/SWS; rapid eye move-
ment (REM) sleep: percentage of TST spent in REM sleep; 
REM, min: time in min spent in REM sleep; sleep efficiency: 
ratio between TST and time spent in bed; arousal index (ArI): 
number of arousals divided by hours of TST. These variables 
are routinely used in clinical practice to describe both sleep 
continuity and sleep architecture. The PSG variables were con-
sidered as continuous variables. SWS, min; REM, min; and 
ArI were log-transformed (natural log) for analysis. Although 
extremes of sleep duration were previously associated with ad-
verse cardiovascular risk outcomes, TST was also evaluated as 
a continuous variable given the low prevalence of long sleepers 
(0.3% slept more than 10 h) and short sleepers (8% slept less 
than 5 h) in the HypnoLaus study. However, we also compared 
the short sleepers and long sleepers, stratifying the subjects in 
four groups according to the TST: < 6, 6–6.9, 7–7.9, and ≥ 8 h. 
These analyses are presented in the supplemental material.
At a second step, two multivariate models were used: the first 
was adjusted for age, sex, and day of PSG recording; the second 
model was adjusted for the same variables plus the following 
additional covariates: smoking, alcohol use, regular exercise, 
depression, and use of medications that affect sleep (hypnotics, 
benzodiazepines, antidepressants, neuroleptics and/or antihis-
tamines). BMI was included as a covariate for hypertension and 
diabetes, but not for the MS because BMI is strongly associ-
ated with abdominal obesity and overadjustment might occur. 
A multivariate analysis with subjects stratified in groups ac-
cording to the TST (< 6, 6–6.9, 7–7.9, and ≥ 8 h) was also per-
formed, and results are presented in the supplemental material.
When studying the association between sleep and cardiovas-
cular morbidity and mortality, SDB constitutes a key pheno-
type as it is an independent risk factor for hypertension25 and 
insulin resistance,26 and is associated with the MS.27 SDB de-
scribes a group of disorders characterized by abnormalities of 
respiratory patterns during sleep. These abnormalities cause 
sleep disturbances (secondary to arousals to resume normal 
ventilation) and/or repetitive oxygen desaturations. Intermit-
tent hypoxia in SDB seems to be a critical factor in the patho-
physiology of cardiovascular and metabolic consequences.13 
Because the purpose of this study was to determine if sleep 
structure is associated with cardiovascular risk factors inde-
pendently of the origin of sleep disruption, we analyzed these 
associations first in the entire group and then, after excluding 
subjects with a substantial (> 15/h) ODI. We choose a cutoff 
value of 15/h as the International Classification of Sleep Dis-
orders (ICSD-3) diagnostic criteria for sleep apnea are based 
on this metric (AHI ≥ 15/h or ≥ 5/h with symptoms).28 Of note, 
ODI was also examined as a continuous variable, with the re-
sults yielding similar conclusions. For simplicity, we present 
only the results using the dichotomous ODI variable.
Multiple testing problems are in a wide variety, ranging 
from testing multiple doses and endpoints jointly, composite 
endpoint, noninferiority and superiority, etc.29 In this study, 
we chose to adjust for multivariate adjustment within each 
MS component, thus allowing a better control of the type I 
error rate while not overtly reducing the chances of finding 
clinically important (and statistically significant) associations. 
We estimated that within each MS component approximately 
20 associations would be tested, thus leading to an adjusted 
P value of 0.05/20 = 0.001 (Bonferroni method).
RESULTS
Feasibility and Failures
Of the 3,051 contacted subjects, 2,168 (71.1%) agreed to have 
a PSG at home. Subjects who agreed to participate were 8.2 y 
younger and reported less sleepiness than those who declined. 
BMI (+0.4 kg/m2) and PSQI scores (+0.3 pts) were slightly 
higher in those who declined (Cohen d test effect size 0.09 for 
both). The Berlin score was similar in both groups. Technical 
problems resulting in insufficient data for PSG scoring were 
encountered in 60 cases (2.8%), 54 PSG were repeated and 6 
subjects declined to repeat the study, resulting in 2,162 partici-
pants (51.2% women, mean age 58.4 ± 11.1 y) included in the 
final analysis (Figure 1).
General Characteristics
Table 1 summarizes the findings for the entire popula-
tion and in subjects with an ODI ≤ 15/h versus those with 
an ODI > 15/h. Overall a total of 30.5% individuals had MS, 
41.5% hypertension, 9.9% diabetes, 41.1% were overweight 
(25 ≤ BMI < 30 kg/m2), and 16.5% were obese (BMI ≥ 30 
kg/m2). The mean TST was 401.2 ± 72.1 min, the time spent 
in SWS and REM sleep were, respectively, 19.7 ± 8.4% and 
21.8 ± 6.1% of the TST, the sleep efficiency was 84.6 ± 10.9%, 
the ArI was 21.3 ± 11/h of sleep, and the AHI was 15.5 ± 16.3/h.
A total of 751 subjects (34.7% of the sample) had a signif-
icant ODI (> 15/h of sleep). Subjects with ODI > 15/h were 
older, more frequently male, had higher rates of MS, hyper-
tension, diabetes, and overweight/obesity than subjects with 
Figure 1—Studied population.
COLAUS II
N = 5,064
Invited for PSG
N = 3,051
Accepted PSG
N = 2,168
Refused PSG
N = 883
Technical PSG
problems
N = 60
Accepted to redo
PSG
N = 54
Excluded
N = 6
Included subjects
with PSG
N = 2,162
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an ODI ≤ 15/h. Concerning PSG characteristics, subjects with 
ODI > 15/h slept less, spent less time in SWS and REM sleep, 
had lower sleep efficiency, and higher ArI.
Sleep Structure and CVD Risk Factors
The tables show the sleep characteristics of subjects ac-
cording to the presence or absence of the MS, hypertension, 
diabetes, and overweight/obesity in the overall sample and in 
subjects without clinically significant desaturation (ODI ≤ 15/h) 
either from unadjusted models (Tables S1 and S2, supple-
mental material) or from models adjusted for age, sex, and day 
of week of the PSG recording (marked by an asterisk in Tables 
2–9), and smoking, alcohol, physical activity, and drugs that 
affect sleep and depression (marked by a dagger in Tables 2–9).
In bivariate analyses subjects with MS had lower TST, spent 
less time in SWS and in REM sleep, and had poorer sleep effi-
ciency and higher ArI than those without MS. The differences 
were attenuated after adjusting for age, sex, and the day on 
which the recording was performed (Tables 2 and 3). Finally, 
only the ArI remained significantly different after additional 
adjustments (adjusted means: 20.2 ± 0.3 versus 22.9 ± 0.5/h; 
P < 0.001). However, the difference lost statistical significance 
in subjects with an ODI ≤ 15/h (P = 0.72).
In the whole group, hypertension was associated with lower 
TST, decreased SWS and REM sleep, lower sleep efficiency, 
and higher ArI. Sleep efficiency was different in subjects with 
hypertension when compared with those without hypertension 
after adjusting for age, sex, and the day of the PSG recording 
(85.1 ± 0.3 versus 84.2 ± 0.4%; P < 0.05), but no significant dif-
ferences were found between groups concerning sleep struc-
ture after adjusting for additional covariates (BMI, smoking, 
alcohol, physical activity, drugs that affect sleep and depres-
sion) (Tables 4 and 5). In subjects without clinically significant 
ODI, hypertension was associated with slightly lower sleep ef-
ficiency in the multivariable adjusted model (adjusted means: 
86.9 ± 0.3% versus 85.4 ± 0.5%; P = 0.02).
Unadjusted analyses showed significant differences in sleep 
structure between subjects with diabetes when compared with 
subjects without diabetes: they spent less time in SWS and in 
REM sleep, and had lower sleep efficiency and higher ArI. In 
the multivariable adjusted model only TST and sleep efficiency 
remained slightly different between groups (Tables 6 and 7). 
In subjects with an ODI ≤ 15/h, after adjusting for potential 
confounders, the differences showed a marginal trend (P = 0.11 
for TST; P = 0.07 for sleep efficiency).
Unadjusted comparisons of sleep structure showed that sub-
jects with a BMI > 25 kg/m2 had lower TST, spent less time in 
SWS and in REM sleep, and had poorer sleep efficiency and 
higher ArI than those with a normal weight. These differences 
were attenuated in the multivariable adjusted model, but % of 
Table 1—Demographic, clinical, and polysomnographic characteristics of the participants.
All Subjects with ODI ≤ 15/h Subjects with ODI > 15/h P a
N 2,162 (100%) 1,411 (65.3%) 751 (34.7%)
Age, y 58.4 ± 11.1 56.3 ± 10.6 62.8 ± 10.8  < 0.001
Female sex 1,106 (51.2%) 866 (61.4%) 240 (31.9%)  < 0.001
Metabolic syndrome 659 (30.5%) 284 (20.1%) 375 (50.0%)  < 0.001
Hypertension 897 (41.5%) 462 (32.7%) 435 (58.0%)  < 0.001
Diabetes 214 (9.9%) 82 (5.8%) 132 (17.5%)  < 0.001
BMI, kg/m2 26.2 ± 4.4 25 ± 3.9 28.5 ± 4.4  < 0.001
< 25 909 (42.3%) 764 (54.3%) 145 (19.3%)  < 0.001
25–30 884 (41.1%) 509 (36.2%) 375 (49.9%)  < 0.001
> 30 356 (16.5%) 134 (9.5%) 222 (29.5%)  < 0.001
Smokers/ex-smokers 1,233 (58.2%) 785 (56.7%) 448 (61.2%)  < 0.05
Regular alcool consumption 1,686 (78.0%) 1,078 (76.4%) 608 (80.9%)  < 0.01
Sedentary 1,047 (55.7%) 662 (52.7%) 385 (61.7%)  < 0.001
Taking drugs that influence sleep b 400 (18.5%) 250 (17.7%) 150 (20.0%)  < 0.01
Depression (lifetime or current) 284 (14.8%) 184 (14.6%) 100 (15.1%)  < 0.05
TST, min 401.2 ± 72.1 406.5 ± 45.3 391 ± 74.2  < 0.001
SWS, % of TST 19.7 ± 8.4 21.0 ± 8.1 17.2 ± 8.4  < 0.001
SWS, min 78.6 ± 34.8 84.6 ± 33.1 67.1 ± 35.1  < 0.001
REM, % of TST 21.8 ± 6.1 22.7 ± 5.7 20.2 ± 6.6  < 0.001
REM, min 88.6 ± 31.1 93.2 ± 29.8 80.1 ± 31.6  < 0.001
Sleep efficiency, % 84.6 ± 10.9 86.1 ± 9.9 81.7 ± 11.9  < 0.001
Arousal index, n/h 21.3 ± 11.0 17.6 ± 7.9 28.3 ± 12.6  < 0.001
AHI, n/h 15.5 ± 16.3 6.9 ± 14.9 31.8 ± 17.6  < 0.001
ODI n/h 14.7 ± 15.2 6.4 ± 10.6 30.5 ± 16.1  < 0.001
Results are expressed as N (%) or mean ± standard deviation. a Comparing ODI ≤ 15/h with ODI > 15/h. b Drugs that influence sleep were considered 
as “present” if participants were using benzodiazepines or derivates (ATC codes: N05BA, N05CD, N03AE), hypnotics (N05CF), antidepressants (N06A), 
neuroleptics (N05A) or antihistamines (R06A). AHI, apnea-hypopnea index; BMI, body mass index; ODI, oxygen desaturation (≥ 3%) index; REM, rapid 
eye movement sleep; sleep efficiency = TST / time spent in bed × 100; SWS, slow wave sleep/stage N3; TST, total sleep time/sleep duration.
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SWS (20.8 ± 0.3 versus 19.5 ± 0.3%; P = 0.002), time spent in 
SWS (82 ± 1 versus 78 ± 1 min, P < 0.05) and the ArI (19.6 ± 0.4 
versus 22 ± 0.3/h; P < 0.001) remained different (Tables 8 and 
9). In subjects with an ODI ≤ 15/h, the percentage and the time 
spent in REM sleep were higher in overweight/obese subjects 
(adjusted means: 22.4 ± 0.2% versus 23.4 ± 0.2%, P = 0.002; 
91 ± 1 versus 97 ± 1 min, P < 0.005), even though these differ-
ences were small.
As previous population studies suggest a U-shaped rela-
tionship between subjective sleep duration and cardiovascular 
outcomes, we performed further analysis stratifying the sub-
jects in four groups according to the TST: < 6, 6–6.9, 7–7.9, 
Table 3—Sleep characteristics according to the absence or presence of metabolic syndrome in subjects without significant oxygen desaturation index 
(≤ 15/h).
Absent * Present * P * Absent † Present † P †
Group size 1,127 284 1,127 284
TST, min 406 ± 2 409 ± 4 0.49 405 ± 2 409 ± 5 0.39
SWS, % of TST 21.1 ± 0.2 21.1 ± 0.5 0.99 21.3 ± 0.3 21.4 ± 0.6 0.89
SWS, min a 85 ± 1 85 ± 2 0.99 85 ± 1 86 ± 2 0.78
REM, % of TST 22.8 ± 0.2 22.5 ± 0.3 0.45 22.8 ± 0.2 22.9 ± 0.4 0.97
REM, min a 93 ± 1 94 ± 2 0.90 93 ± 1 95 ± 2 0.48
Sleep efficiency, % 86.2 ± 0.3 86.4 ± 0.6 0.73 86.2 ± 0.3 87.3 ± 0.6 0.12
Arousal index, n/h a 17.4 ± 0.2 17.5 ± 0.5 0.97 17.4 ± 0.2 17.1 ± 0.5 0.72
Results are expressed as multivariable adjusted mean ± standard error. *Adjusted for sex, age, and day of week (Friday). † Adjusted for sex, age, day of 
week (Friday), smoking, alcohol, physical activity, drugs that affect sleep and depression. a Between-group comparisons performed using log-transformed 
data. Statistical analysis by analysis of variance. α level set at P < 0.001. REM, rapid eye movement sleep; sleep efficiency = TST / time spent in bed × 100; 
SWS, slow wave sleep/stage N3; TST, total sleep time/sleep duration.
Table 2—Sleep characteristics according to the absence or presence of metabolic syndrome in the entire population.
Absent * Present * P * Absent † Present † P †
Group size 1,503 659 1,503 659
TST, min 401 ± 2 401 ± 3 0.79 400 ± 2 401 ± 3 0.72
SWS, % of TST 20.0 ± 0.2 19.3 ± 0.3 0.07 20.3 ± 0.2 19.7 ± 0.4 0.18
SWS, min a 80 ± 1 77 ± 1 0.12 81 ± 1 78 ± 1 0.42
REM, % of TST 22.2 ± 0.2 21.4 ± 0.2  < 0.01 22.2 ± 0.2 21.7 ± 0.3 0.09
REM, min a 90 ± 1 87 ± 1 0.04 90 ± 1 88 ± 1 0.32
Sleep efficiency, % 84.9 ± 0.3 84.3 ± 0.4 0.19 84.8 ± 0.3 85.1 ± 0.4 0.57
Arousal index, n/h a 20.3 ± 0.3 23.3 ± 0.4  < 0.001 20.2 ± 0.3 22.9 ± 0.5  < 0.001
Results are expressed as multivariable adjusted mean ± standard error. *Adjusted for sex, age, and day of week (Friday). † Adjusted for sex, age, day of 
week (Friday), smoking, alcohol, physical activity, drugs that affect sleep and depression. a Between-group comparisons performed using log-transformed 
data. Statistical analysis by analysis of variance. α level set at P < 0.001. REM, rapid eye movement sleep; sleep efficiency = TST / time spent in bed × 100; 
SWS, slow wave sleep/stage N3; TST, total sleep time/sleep duration.
Table 4—Sleep characteristics according to the absence or presence of hypertension in the entire population.
Absent * Present * P * Absent † Present † P †
Group size 1,263 897 1,263 897
TST, min 402 ± 2 400 ± 3 0.53 402 ± 2 398 ± 3 0.31
SWS, % of TST 19.9 ± 0.2 19.7 ± 0.3 0.57 20.1 ± 0.3 20.1 ± 0.3 0.88
SWS, min a 80 ± 1 78 ± 1 0.24 80 ± 1 79 ± 1 0.44
REM, % of TST 22.1 ± 0.2 21.8 ± 0.2 0.33 22.1 ± 0.2 21.9 ± 0.2 0.53
REM, min a 90 ± 1 88 ± 1 0.19 90 ± 1 88 ± 1 0.23
Sleep efficiency, % 85.1 ± 0.3 84.2 ± 0.4  < 0.05 85.2 ± 0.3 84.5 ± 0.4 0.16
Arousal index, n/h a 20.8 ± 0.3 21.7 ± 0.4 0.24 20.7 ± 0.3 21.2 ± 0.4 0.77
Results are expressed as multivariable adjusted mean ± standard error. *Adjusted for sex, age, and day of week (Friday). † Adjusted for sex, age, day of 
week (Friday), smoking, alcohol, physical activity, body mass index, and drugs that affect sleep and depression. a Between-group comparisons performed 
using log-transformed data. Statistical analysis by analysis of variance. α level set at P < 0.001. REM, rapid eye movement sleep; sleep efficiency = TST / 
time spent in bed × 100; SWS, slow wave sleep/stage N3; TST, total sleep time/sleep duration.
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and ≥ 8 h. These data are presented in the supplemental ma-
terial (Tables S3 to S6). In this analysis the most consistent 
finding was that the prevalence of hypertension showed an 
inverse association with sleep duration for the whole group, 
and a U-shaped association in subjects without significant ODI 
(Tables S3 and S4). However, in the multivariate logistic re-
gression analysis (Tables S5 and S6) after adjusting for sex, 
age, smoking, alcohol, physical activity, drugs that affect sleep, 
BMI, and depression, the odds ratio (95% confidence interval) 
for hypertension for subjects sleeping less than 6 h was 1.19 
(0.87–1.62) for the entire population and 1.45 (0.97–2.16) for 
those without significant ODI, taking as reference subjects 
with a sleep duration of 7–8 h. Significant differences between 
groups were found for the prevalence of the MS in the entire 
Table 5—Sleep characteristics according to the absence or presence of hypertension in subjects without significant oxygen desaturation index (≤ 15/h).
Absent * Present * P * Absent † Present † P †
Group size 949 462 949 462
TST, min 409 ± 2 401 ± 3  < 0.05 408 ± 2 400 ± 4 0.08
SWS, % of TST 21.1 ± 0.3 21.3 ± 0.4 0.74 21.2 ± 0.3 21.6 ± 0.4 0.49
SWS, min a 86 ± 1 84 ± 2 0.28 86 ± 1 85 ± 2 0.64
REM, % of TST 22.8 ± 0.2 22.7 ± 0.3 0.90 22.9 ± 0.2 22.8 ± 0.3 0.79
REM, min a 94 ± 1 92 ± 1 0.23 94 ± 1 92 ± 2 0.26
Sleep efficiency, % 86.8 ± 0.3 85.1 ± 0.5  < 0.005 86.9 ± 0.3 85.4 ± 0.5 0.02
Arousal index, n/h a 17.7 ± 0.3 16.9 ± 0.4 0.17 17.7 ± 0.3 16.6 ± 0.4 0.09
Results are expressed as multivariable adjusted mean ± standard error. *Adjusted for sex, age, and day of week (Friday). † Adjusted for sex, age, day of 
week (Friday), smoking, alcohol, physical activity, body mass index, and drugs that affect sleep and depression. a Between-group comparisons performed 
using log-transformed data. Statistical analysis by analysis of variance. α level set at P < 0.001. REM, rapid eye movement sleep; sleep efficiency = TST / 
time spent in bed × 100; SWS, slow wave sleep/stage N3; TST, total sleep time/sleep duration.
Table 7—Sleep characteristics according to the absence or presence of diabetes, in subjects without significant oxygen desaturation index (≤ 15/h).
Absent * Present * P * Absent † Present † P †
Group size 1,329 82 1,329 82
TST, min 406 ± 2 413 ± 8 0.38 405 ± 2 419 ± 8 0.11
SWS, % of TST 21.1 ± 0.2 21.6 ± 0.9 0.64 21.3 ± 0.2 20.9 ± 1.0 0.69
SWS, min a 85 ± 1 86 ± 4 0.81 85 ± 1 85 ± 4 0.61
REM, % of TST 22.8 ± 0.2 21.7 ± 0.6 0.08 22.9 ± 0.2 21.8 ± 0.7 0.13
REM, min a 94 ± 1 92 ± 3 0.95 94 ± 1 93 ± 4 0.70
Sleep efficiency, % 86.2 ± 0.3 86.9 ± 1.1 0.58 86.3 ± 0.3 88.4 ± 1.1 0.07
Arousal index, n/h a 17.4 ± 0.2 17.5 ± 0.9 0.83 17.3 ± 0.2 17.7 ± 1 0.67
Results are expressed as multivariable adjusted mean ± standard error. *Adjusted for sex, age, and day of week (Friday). † Adjusted for sex, age, day of 
week (Friday), smoking, alcohol, physical activity, body mass index, and drugs that affect sleep and depression. a Between-group comparisons performed 
using log-transformed data. Statistical analysis by analysis of variance. α level set at P < 0.001. REM, rapid eye movement sleep; sleep efficiency = TST / 
time spent in bed × 100; SWS, slow wave sleep/stage N3; TST, total sleep time/sleep duration.
Table 6—Sleep characteristics according to the absence or presence of diabetes, in the entire population.
Absent * Present * P * Absent † Present † P †
Group size 1,948 214 1,948 214
TST, min 401 ± 2 407 ± 5 0.20 399 ± 2 413 ± 6 0.02
SWS, % of TST 19.9 ± 0.2 19.3 ± 0.6 0.32 20.1 ± 0.2 20.2 ± 0.7 0.92
SWS, min a 79 ± 1 77 ± 2 0.25 80 ± 1 81 ± 3 0.58
REM, % of TST 22.0 ± 0.1 21.2 ± 0.4 0.06 22.1 ± 0.1 21.7 ± 0.5 0.43
REM, min a 89 ± 1 87 ± 2 0.86 89 ± 1 90 ± 2 0.25
Sleep efficiency, % 84.7 ± 0.2 85.0 ± 0.7 0.65 84.8 ± 0.2 86.5 ± 0.8 0.04
Arousal index, n/h a 20.9 ± 0.2 24.0 ± 0.7  < 0.005 20.9 ± 0.2 21.8 ± 0.8 0.30
Results are expressed as multivariable adjusted mean ± standard error. *Adjusted for sex, age, and day of week (Friday). † Adjusted for sex, age, day of 
week (Friday), smoking, alcohol, physical activity, body mass index, and drugs that affect sleep and depression. a Between-group comparisons performed 
using log-transformed data. Statistical analysis by analysis of variance. α level set at P < 0.001. REM, rapid eye movement sleep; sleep efficiency = TST / 
time spent in bed × 100; SWS, slow wave sleep/stage N3; TST, total sleep time/sleep duration.
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group, as subjects with a TST < 6 h had a higher prevalence 
of MS than the other groups (no U-shaped relationship), but 
this difference was not found in subjects without significant 
ODI (≤ 15/h). No significant differences between groups were 
found in the multivariate logistic regression analysis. No U-
shaped association was found between groups concerning the 
prevalence of diabetes. In the multivariate logistic regression 
analysis, the OR for diabetes was lower in subjects with a TST 
less than 6 h compared with the reference group (OR 0.57, CI: 
0.35–0.93) in the entire group, but not in the subjects without 
significant SDB. Finally, a U-shaped association was found for 
the prevalence of BMI > 25 kg/m2 in the whole group, but not 
when considering subjects with ODI ≤ 15/h. However, in the 
multivariate logistic regression analysis the OR for a BMI > 25 
kg/m2 was significantly higher in subjects with a TST more 
than 8 h and no significant ODI, when compared with the ref-
erence group (1.63 (1.09–2.43)). Overall, these analyses con-
firm that TST, whether used as a continuous or a categorical 
variable, does not show consistent associations with CVD risk 
factors.
DISCUSSION
To the best of our knowledge, this is one of the largest 
population-based studies assessing the relationship between 
sleep variables, objectively measured by PSG, and CV risk 
factors, specifically, MS, hypertension, diabetes, and obe-
sity. In our study, MS was more prevalent in subjects whose 
sleep was shorter, lighter (as measured by decreased SWS and 
REM sleep), more fragmented, and with lower sleep efficiency. 
However, these differences were attenuated when adjusting for 
potential confounding factors and only the ArI remained sig-
nificantly higher in subjects with the MS in the multivariate 
model. This association disappeared in subjects without sig-
nificant ODI (clinical cutoff of ODI ≤ 15/h), suggesting that the 
increased ArI in subjects with MS could be related to the pres-
ence of respiratory disturbances. Another possible explanation 
is that restricting the analysis to subjects with ODI ≤ 15 leads 
to a reduction in the sample size, and decreased the statistical 
power to detect differences between groups.
Crude unadjusted analyses also showed significant dif-
ferences in sleep duration and structure between subjects 
according to the presence or absence of hypertension, dia-
betes, and overweight/obesity. But, as for MS, these differ-
ences disappeared in subjects without significant ODI after 
controlling for confounders. In a conservative approach to 
avoid the possibility of finding significant differences due to 
chance we preferred a value of P < 0.001 for statistical sig-
nificance. Choosing a less rigorous value of P < 0.05 leads to a 
Table 8—Sleep characteristics according to the absence or presence of overweight/obesity (body mass index ≥ 25 kg/m2) in the entire population.
Absent * Present * P * Absent † Present † P †
Group size 909 1,240 909 1,240
TST, min 399 ± 2 402 ± 2 0.27 399 ± 2 401 ± 2 0.46
SWS, % of TST 20.7 ± 0.3 19.2 ± 0.2  < 0.001 20.8 ± 0.3 19.5 ± 0.3 0.002
SWS, min a 82 ± 1 77 ± 1  < 0.01 82 ± 1 78 ± 1  < 0.05
REM, % of TST 21.9 ± 0.2 22.0 ± 0.2 0.62 21.8 ± 0.2 22.3 ± 0.2 0.09
REM, min a 88 ± 1 90 ± 1 0.34 88 ± 1 90 ± 1 0.09
Sleep efficiency, % 85.0 ± 0.3 84.5 ± 0.3 0.28 85.0 ± 0.4 84.9 ± 0.3 0.80
Arousal index, n/h a 19.5 ± 0.3 22.4 ± 0.3  < 0.001 19.6 ± 0.4 22.0 ± 0.3  < 0.001
Results are expressed as multivariable adjusted mean ± standard error. *Adjusted for sex, age, and day of week (Friday). † Adjusted for sex, age, day of 
week (Friday), smoking, alcohol, physical activity, drugs that affect sleep and depression. a Between-group comparisons performed using log-transformed 
data. Statistical analysis by Student t test or analysis of variance. α level set at P < 0.001. REM, rapid eye movement sleep; sleep efficiency = TST / time 
spent in bed × 100; SWS, slow wave sleep/stage N3; TST, total sleep time/sleep duration.
Table 9—Sleep characteristics according to the absence or presence of overweight/obesity (body mass index ≥ 25 kg/m2), in subjects without significant 
oxygen desaturation index (≤ 15/h).
Absent * Present * P * Absent † Present † P †
Group size 764 643 764 643
TST, min 403 ± 2 410 ± 3 0.06 403 ± 3 409 ± 3 0.12
SWS, % of TST 21.6 ± 0.3 20.6 ± 0.3  < 0.05 21.7 ± 0.3 20.8 ± 0.4 0.06
SWS, min a 86 ± 1 84 ± 1 0.23 86 ± 1 84 ± 1 0.37
REM, % of TST 22.5 ± 0.2 23.1 ± 0.2  < 0.05 22.4 ± 0.2 23.4 ± 0.2 0.002
REM, min a 92 ± 1 96 ± 1  < 0.01 91 ± 1 97 ± 1  < 0.005
Sleep efficiency, % 86.3 ± 0.3 86.2 ± 0.4 0.90 86.3 ± 0.4 86.5 ± 0.4 0.63
Arousal index, n/h a 17.0 ± 0.3 17.9 ± 0.3 0.09 17.1 ± 0.3 17.6 ± 0.3 0.47
Results are expressed as multivariable adjusted mean ± standard error. *Adjusted for sex, age, and day of week (Friday). † Adjusted for sex, age, day of 
week (Friday), smoking, alcohol, physical activity, drugs that affect sleep and depression. a Between-group comparisons performed using log-transformed 
data. Statistical analysis by Student t test or analysis of variance. α level set at P < 0.001. REM, rapid eye movement sleep; sleep efficiency = TST / time 
spent in bed × 100; SWS, slow wave sleep/stage N3; TST, total sleep time/sleep duration.
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statistically significant association between hypertension and 
sleep efficiency, in subjects without significant ODI and after 
adjusting for possible confounding factors; yet, these differ-
ences are very small (86.9 ± 0.3% versus 85.4 ± 05%, P = 0.02). 
In the same way, overweight subjects without significant ODI 
spent more time in REM sleep, but again these differences 
were small (22.4 ± 0.2% versus 23.4 ± 0.2%, P = 0.002; 91 ± 1 
versus 97 ± 1 min, P < 0.005). As indicated by others,10 such 
small differences in epidemiological studies, even if statisti-
cally significant, are of questionable clinical value because this 
association must be the result of long-term sleeping habits, and 
can be easily modified by other behavioral factors, as short 
exercise exposures or dietary changes. These findings suggest 
that normal variation in sleep duration and structure does not 
seem to be associated with MS, hypertension, diabetes, and 
obesity.
Indirect evidence suggests that sleep deprivation may trigger 
biological changes contributing to MS. Laboratory studies 
demonstrated that reduced sleep amount produces short-term 
adverse effects, such as changes in circulating levels of leptin 
and ghrelin, impaired glucose tolerance, increased cortisol se-
cretion, altered growth hormone metabolism, and changes in 
BP and sympathetic activity.30,31 Also, changes in sleep struc-
ture, suppression of SWS in particular, without any change in 
TST, resulted in decreased insulin sensitivity and reduced glu-
cose tolerance.11 In the same way, Sayk et al.12 showed that se-
lective deprivation of SWS for 1 night by acoustic stimulation 
in healthy subjects produces a significant reduction in BP dip-
ping, but no significant changes in morning BP, urine catechol-
amine excretion, or HR variability. It should be noted that in 
laboratory studies, the carefully controlled experimental con-
ditions allow changes in sleep patterns (as major shortening of 
the sleep duration that cannot be tolerated beyond a few days 
or the complete absence of SWS) that are not experienced in 
everyday life in the general population. Additionally, in most 
of these studies subjects are selected on the basis of the ab-
sence of sleep disorders and other comorbidities that can have 
a significant effect on the development of CVD risk factors.
Our observations differ from those of previous epidemio-
logical surveys that have identified several associations be-
tween sleep and adverse cardiovascular risk factors. Almost 
all epidemiologic studies examining these associations used 
subjective sleep assessments, such as self-reported sleep dura-
tion, which may lead to major methodological issues consid-
ering that there is no validated evidence for direct relationships 
between subjective and objective measures of sleep. The cor-
relation between self-reported and objectively measured sleep 
was shown to be, at best, moderate, and biased by systematic 
overreporting.32 Comparing self-reports of sleep duration with 
those obtained by wrist actigraphy shows that people subjec-
tively overestimated their sleep by up to 1 h, with R2 values 
between these two indices being only 0.22. People estimating 
their sleep at 5 h usually only slept about 4 h, and those esti-
mating 7 h only slept about 6.6 h.32 Self-perceived sleep dura-
tion is likely to be influenced by factors such as sleep disorders, 
sociodemographic profile, social demands, or measures time 
in bed instead of actual sleep duration.
As pointed out by Kurina et al.,33 in a recent critical review 
of the studies looking at the association between sleep duration 
and mortality, another major issue is that different definitions 
are used for long and short sleep. Short sleep duration in dif-
ferent studies varied from 4 h or fewer, to fewer than 7 h per 
night, and long sleep from more than 8 h to 12 h or longer. The 
reference “normal” category varied from 7 to 9 h. From some 
previous studies causal inference is also difficult to draw be-
cause of the lack of control for major confounders.
Only a limited number of studies analyzed the relation-
ship between objectively measured sleep patterns by PSG 
and morbidity-mortality. In a prospective study of 184 older 
adults, Dew et al.34 showed that short sleepers (< 6 h) did not 
have significantly higher mortality than the rest of the sample. 
However, increased mortality was associated with sleep la-
tency > 30 min, sleep efficiency < 80%, and SWS < 1%. The 
percentage of SWS was not associated with mortality after 
controlling for age, sex, and baseline medical burden and the 
potential role of other possible confounders, as the presence of 
SDB, was not analyzed. In addition, in older adults a prospec-
tive analysis of 784 subjects participating in the Outcomes of 
Sleep Disorders in Older Men Study revealed that the amount 
of time spent in SWS was inversely related to the development 
of incident hypertension independently of sleep duration and 
SDB, and after adjusting for age, race and body mass index.35 
From the same cohort, PSG data from 2,745 older men also 
showed a significant inverse association between quartiles of 
SWS and BMI but the association was attenuated in men with 
a respiratory disturbance index ≥ 15/h.36 These studies suggest 
a possible relationship between SWS and hypertension and 
obesity in selected populations (older men), but they cannot be 
generalized to the overall population.
Data from the Penn State cohort showed that individuals 
with insomnia who slept < 6 h had a significantly increased risk 
of type 2 diabetes,37 hypertension,38 and mortality39 compared 
to the “normal sleep duration, no insomnia” group, after ad-
justing for confounders. Insomnia with objectively measured 
short sleep duration but not normal variation in sleep seems to 
constitute a vulnerability sleep associated phenotype. In a re-
cently published prospective study on this cohort, self-reported 
short sleep duration, but not objective sleep duration, was as-
sociated with a significant increased risk of incident obesity.40 
Again, perception of one’s sleep, as a surrogate marker of 
emotional stress and subjective sleep disturbances rather than 
objective sleep duration, seems to be the underlying factor be-
yond the association.
Two previous studies specifically analyzed the association 
between sleep and MS using PSG. Nock et al.41 analyzed PSG 
data from 533 adults participating in the Cleveland Family 
Sleep Study. The subjects were selected from families with 
siblings having extreme high or low values for AHI. The au-
thors found that sleep disturbance was a significant component 
of MS. They defined a sleep disturbance factor that included 
four measures: the AHI, the ArI, the percentage of sleep time 
when oxygen saturation was less than 90%, and the SWS%. 
Again, disturbances in sleep but not normal sleep were identi-
fied as the risk factors. More recently, Hall et al.42 analyzed 
the association between sleep and MS in a group of 368 mul-
tiethnic middle-aged women (mean age, 51 y) participating 
in the SWAN Sleep Study. They analyzed various sleep pa-
rameters derived from PSG including EEG power spectral 
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analysis. In bivariate analyses, MS was associated with de-
creased sleep duration and efficiency and increased beta power 
in NREM sleep and AHI. When entered simultaneously in a 
multivariable adjusted model to evaluate their independent 
contributions, only sleep efficiency and AHI appeared to be 
independent correlates of MS. Respiratory disturbances seem 
to be clearly associated with MS, as evidenced in our study and 
in previous studies,27,43 but the sleep efficiency is unrelated to 
MS in our study after adjusting for confounders. Nevertheless, 
we did find a non- statistically significant association between 
hypertension and sleep efficiency, which was lower in subjects 
with hypertension. One main explanation for this discrepancy 
is that we included men and women in our study, whereas Hall 
et al.42 only included women. In addition, our subjects were 
older and had a higher AHI.
Strengths and Limitations
The major strengths of our study is its population-based 
design, the large sample size, the availability of detailed in-
formation on a number of potential confounders, and the use 
of PSG to obtain objective measures of sleep structure and 
sleep comorbidities as SDB. Nevertheless, we acknowledge 
potential limitations. First, our results are based on a single 
PSG, and even if the PSG is considered the gold standard for 
sleep studies, a single recorded night may not fully capture 
the complexity of a phenomenon such as sleep. Night-to-night 
variability in sleep is observed in subjects who undergo PSG 
related to the so called “first night effect”, which can be caused 
by discomfort caused by electrodes, limitation of movements, 
and the unfamiliar environment of the sleep laboratory.44 
Thus, in order to limit the effect of the first night effect, we 
performed the PSG at home under “habitual” sleeping envi-
ronment, and subjects were instructed to maintain their usual 
sleeping habits. Further, we repeated the PSG in a randomly 
selected sample of 20 HypnoLaus participants to determine 
the short-term variability of 2 nights of home PSG. Only the 
percentage of TST spent in REM sleep was marginally dif-
ferent between nights (21.4 ± 6.7 versus 24 ± 5%, P = 0.04, 
Table S7, supplemental material). Repeated home PSG in the 
Sleep Heart Health Study cohort revealed similar results, with 
no evidence of a major “first-night effect”.45 Second, the Hyp-
noLaus study is a monocentric study allowing uniform collec-
tion, processing, and analysis of the data, but it is limited to 
middle-aged and elderly Lausanne residents; thus, the results 
may not be easily extrapolated to other populations. Finally, 
this is a cross-sectional study and future prospective studies 
are needed to build on the current findings.
In conclusion, in this population-based study, we found sig-
nificant associations between sleep duration and quality and 
MS, hypertension, diabetes, and obesity. However, these as-
sociations are not independent of other known CVD risk fac-
tors, as age, sex, sedentary life style, obesity, ODI, depression, 
smoking, alcohol, or use of medications that affect sleep. We 
conclude that normal variations in sleep in adults seem to 
contribute little, if at all, to MS, hypertension, diabetes, and 
obesity.
ABBREVIATIONS
AHI, apnea-hypopnea index
ArI, arousal index
ATP-III, Adult Treatment Panel III report
BMI, body-mass index
CVD, cardiovascular disease
DBP, diastolic blood pressure
DIGS, Diagnostic Interview for Genetic Studies
ESS, Epworth Sleepiness Scale
HDL, high-density lipoprotein
MS, metabolic syndrome
ODI, oxygen desaturation index
PSG, polysomnography
PSQI, Pittsburgh Sleep Quality Index
REM, rapid eye movement
SBP, systolic blood pressure
SDB, sleep disordered breathing.
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SUPPLEMENTAL MATERIAL
Table S1—Sleep characteristics according to the absence or presence of cardiovascular disease risk factors in the entire population.
 Metabolic Syndrome Hypertension Diabetes Overweight/Obesity 
Absent Present P Absent Present P Absent Present P Absent Present P
Group size 1,503 659  1,263 897  1,948 214  909 1,240  
TST, min 405 ± 70 393 ± 77 < 0.001 408 ± 71 391 ± 73 < 0.001 402 ± 72 393 ± 74 0.1 405 ± 68 398 ± 75 < 0.05
SWS, % of TST 20.4 ± 8.3 18.1 ± 8.7 < 0.001 20.8 ± 8.1 18.3 ± 8.8 < 0.001 20.0 ± 8.4 17.2 ± 8.8 < 0.001 21.2 ± 8.6 18.7 ± 8.2 < 0.001
SWS, min a 82 ± 34 71 ± 35 < 0.001 84 ± 34 71 ± 35 < 0.001 80 ± 35 67 ± 34 < 0.001 85 ± 35 74 ± 34 < 0.001
REM, % of TST 22.4 ± 5.9 20.6 ± 6.7 < 0.001 22.7 ± 5.7 20.7 ± 6.7 < 0.001 22.1 ± 6.0 19.7 ± 7.4 < 0.001 22.2 ± 5.9 21.6 ± 6.4 < 0.05
REM, min a 91 ± 30 82 ± 33 < 0.001 93 ± 30 82 ± 32 < 0.001 90 ± 31 79 ± 33 < 0.001 90.7 ± 30.3 87.1 ± 31.6 < 0.05
Sleep efficiency, % 85.7 ± 10.3 82.2 ± 11.8 < 0.001 86.8 ± 9.9 81.6 ± 11.5 < 0.001 85 ± 10.8 81.6 ± 11.2 < 0.001 85.9 ± 10.0 83.6 ± 11.5 < 0.001
Arousal index, n/h a 19.7 ± 9.5 25.0 ± 13.3 < 0.001 19.5 ± 9.4 23.9 ± 12.6 < 0.001 20.7 ± 10.4 27.1 ± 14.8 < 0.001 18.7 ± 8.8 23.2 ± 12.1 < 0.001
Unadjusted values. Results are expressed as mean ± standard deviation. a Between-group comparisons performed using log-transformed data. REM, rapid eye movement sleep; sleep 
efficiency = TST / time spent in bed × 100; SWS, slow wave sleep/stage N3; TST, total sleep time/sleep duration.
Table S2—Sleep characteristics according to the absence or presence of cardiovascular disease risk factors in subjects without significant oxygen 
desaturation index (≤ 15/h).
 Metabolic Syndrome Hypertension Diabetes Overweight/Obesity 
Absent Present P Absent Present P Absent Present P Absent Present P
Group size 1,127 284  949 462  1,329 82  764 643  
TST, min 408 ± 69 403 ± 75 0.28 413 ± 68 394 ± 74  < 0.001 407 ± 70 401 ± 81 0.43 406 ± 68 407 ± 73 0.79
SWS, % of TST 21.3 ± 8.1 20.2 ± 8.5  < 0.05 21.5 ± 8.0 20.2 ± 8.5  < 0.005 21.1 ± 8.1 19.9 ± 9.1 0.18 21.7 ± 8.4 20.3 ± 7.8  < 0.05
SWS, min a 86 ± 33 80 ± 33  < 0.005 88 ± 33 78 ± 33  < 0.001 85 ± 33 77 ± 33  < 0.01 87 ± 34 82 ± 33  < 0.01
REM, % of TST 22.9 ± 5.5 21.8 ± 6.6  < 0.005 23.1 ± 5.5 21.8 ± 6.3  < 0.001 22.8 ± 5.6 20.4 ± 7.8  < 0.001 22.5 ± 5.7 22.9 ± 5.9 0.26
REM, min a 94 ± 29 89 ± 33  < 0.05 96 ± 29 87 ± 31  < 0.001 94 ± 29 84 ± 36  < 0.05 92 ± 29 94 ± 30 0.2
Sleep efficiency, % 86.6 ± 9.8 84.5 ± 10.5  < 0.005 87.7 ± 9.0 83.0 ± 11.0  < 0.001 86.3 ± 9.9 83.8 ± 10.3  < 0.05 86.6 ± 9.6 85.7 ± 10.4 0.08
Arousal index, n/h a 17.3 ± 7.6 18.6 ± 8.8  < 0.05 17.3 ± 7.9 18.3 ± 7.9  < 0.05 17.5 ± 7.7 19.8 ± 10.0  < 0.05 17.0 ± 7.4 18.2 ± 8.4  < 0.01
Unadjusted values. Results are expressed as mean ± standard deviation. a Between-group comparisons performed using log-transformed data. REM, rapid eye movement sleep; sleep 
efficiency = TST / time spent in bed × 100; SWS, slow wave sleep/stage N3; TST, total sleep time/sleep duration.
Table S3—Bivariate association between cardiovascular risk factors and total sleep time in the entire 
population.
< 6 h 6–6.9 h 7–7.9 h ≥ 8 h P
Metabolic syndrome
No 352 (62.6) 535 (71.7) 421 (72.3) 195 (71.7) 0.001
Yes 210 (37.4) 211 (28.3) 161 (27.7) 77 (28.3)
Hypertension
No 274 (48.8) 444 (59.5) 366 (63.0) 179 (65.8)  < 0.001
Yes 287 (51.2) 302 (40.5) 215 (37.0) 93 (34.2)
Diabetes
No 492 (87.5) 681 (91.3) 523 (89.9) 252 (92.7) 0.06
Yes 70 (12.5) 65 (8.7) 59 (10.1) 20 (7.4)
BMI > 25 kg/m2
No 217 (38.7) 307 (41.5) 275 (47.4) 110 (40.9) 0.02
Yes 344 (61.3) 432 (58.5) 305 (52.6) 159 (59.1)
Results are expressed as number of participants and (column percentage). Statistical analysis by chi-
square. BMI, body mass index.
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Table 4—Bivariate association between cardiovascular risk factors and total sleep time in subjects 
without significant oxygen desaturation index (≤ 15/h).
< 6 h 6–6.9 h 7–7.9 h ≥ 8 h P
Metabolic syndrome
No 249 (77.1) 394 (80.4) 328 (81.4) 156 (80.0) 0.53
Yes 74 (22.9) 96 (19.6) 75 (18.6) 39 (20.0)
Hypertension
No 181 (56) 332 (67.8) 295 (73.2) 141 (72.3)  < 0.001
Yes 142 (44) 158 (32.2) 108 (26.8) 54 (27.7)
Diabetes
No 299 (92.6) 467 (95.3) 380 (94.3) 183 (93.9) 0.44
Yes 24 (7.4) 23 (4.7) 23 (5.7) 12 (6.2)
BMI > 25 kg/m2
No 178 (55.1) 256 (52.5) 238 (59.2) 92 (47.4) 0.04
Yes 145 (44.9) 232 (47.5) 164 (40.8) 102 (52.6)
Results are expressed as number of participants and (column percentage). Statistical analysis by chi-
square. BMI, body mass index.
Table S5—Multivariate association between cardiovascular risk factors and total sleep time in the entire 
population.
< 6 h 6–6.9 h 7–7.9 h ≥ 8 h
Metabolic syndrome 0.95 (0.70–1.29) 0.90 (0.67–1.19) 1 (ref.) 1.00 (0.67–1.49)
Hypertension 1.19 (0.87–1.62) 1.02 (0.77–1.36) 1 (ref.) 0.94 (0.63–1.41)
Diabetes 0.57 (0.35–0.93) 0.69 (0.43–1.08) 1 (ref.) 0.92 (0.48–1.77)
BMI > 25 kg/m2 1.01 (0.76–1.34) 1.11 (0.87–1.43) 1 (ref.) 1.39 (0.98–1.98)
Results are expressed as odds ratio and (95% confidence interval). Statistical analysis by logistic 
regression adjusting for sex, age, smoking, alcohol, physical activity, drugs that affect sleep and 
depression. For hypertension and diabetes, a further adjustment on BMI was performed. Significant 
values are indicated in bold. BMI, body mass index.
Table S6—Multivariate association between cardiovascular risk factors and total sleep time in subjects 
without significant oxygen desaturation index (≤ 15/h).
6 h 6–6.9 h 7–7.9 h ≥ 8 h
Metabolic syndrome 0.87 (0.56–1.36) 1.00 (0.67–1.48) 1 (ref.) 1.09 (0.65–1.82)
Hypertension 1.45 (0.97–2.16) 1.04 (0.72–1.49) 1 (ref.) 1.05 (0.65–1.69)
Diabetes 0.67 (0.31–1.44) 0.54 (0.26–1.12) 1 (ref.) 1.48 (0.64–3.39)
BMI > 25 kg/m2 0.90 (0.64–1.27) 1.17 (0.86–1.57) 1 (ref.) 1.63 (1.09–2.43)
Results are expressed as odds ratio and (95% confidence interval). Statistical analysis by logistic 
regression adjusting for sex, age, smoking, alcohol, physical activity, drugs that affect sleep and 
depression. For hypertension and diabetes, a further adjustment on BMI was performed. Significant 
values are indicated in bold. BMI, body mass index.
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Table S7—Night-to-night variability in polysomnographic parameters in 
a random selection of 20 subjects participating in the HypnoLaus study 
(mean age: 63.5 ± 11 y).
First Night Second Night P
TST, min 413.5 ± 79.1 402.4 ± 73.8 0.5
SWS, % of TST 17.6 ± 7.5 16.4 ± 7.9 0.17
SWS, min 74 ± 35.7 67.4 ± 36.5 0.12
REM, % of TST 21.4 ± 6.7 24 ± 5 0.04
REM, min 90.6 ± 31.9 98.2 ± 31.6 0.24
Sleep efficiency, % 80.2 ± 9.2 79.3 ± 11.4 0.65
Arousal index, n/h 21.2 ± 8.5 20.1 ± 6.4 0.36
AHI, n/h 22.5 ± 14.7 24.7 ± 17.5 0.32
ODI, n/h 19.5 ± 10.9 21 ± 14.9 0.47
Results are expressed as mean ± standard deviation. AHI, apnea-
hypopnea index; ODI, oxygen desaturation (≥ 3%) index; REM, rapid 
eye movement sleep; sleep efficiency = TST / time spent in bed × 100; 
SWS, slow wave sleep/stage N3; TST, total sleep time/sleep duration.
